Skip to main content

Table 1 Baseline characteristics of the study populations in the 10 studies included in the meta-analysis

From: Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Author year Regimen Age (years) Sample size (females) BMI (kg/m2) HbA1c (%) FBG (mmol/l) Type of diabetes Duration of DM Dose of injected cells Mode of injection Follow-up (months)
Carlsso
n 2015 [23]
hBM-MSCs
Control
24±6
27±6
9(1)
9(4)
23.3±3.3
22.5± 2.7
None None TIDM None 2.75×106/kg IV 12
Yu 2011 [25] hUC-MSCs
Control
19.67±2.58
14.83±8.18
6(3)
6(2)
21.56±1.67
20.08± 3.48
10.53± 0.98
9.16± 3.30
8.23±2.12
8.08±1.83
TIDM 3months 1×107 IV 9
Hu 2013 [26] WJ-MSCs
Control
17.6±33.69
18.2±30.60
15(6)
14(6)
20.9±14.33
21.3±15.71
6.85±2.87
6.79±3.14
5.7±1.71
5.4±1.64
TIDM 6months (2.6±1.2)×107 IV 24
Zhang 2016 [24] AD-MSCs
Control
22. 1 ± 6. 6
21. 6 ± 6. 8
16(7)
17(7)
20.8 ±1.9
21.1±1.9
6.76±1.25
6.71±1.43
5.92 ±1.68
6.13 ±1.49
TIDM 3.5 ±2.9 (months)
3. 7 ± 5. 5 (months)
1×107/kg IV 24
Bhansali 2017 [18] ABM-MSCs
ABM-MSCs
Control
47.9±18.9
44.6±8.9
51.7±13.3
10(2)
10(3)
10(4)
28.8±4.4
27.9±4.5
26.4±3.8
6.8±0.3
6.8±0.8
6.5±0.5
5.8±0.8
6.0±0.8
6.1±1.0
T2DM 15.3±12.7(years)
10.2±1.3(years)
12.5±5.2(years)
(1.2±0.3)×109 SPD artery
Splenic artery
12
Guan 2015 [17] hUC-MSCs 40.5 ± 9.21 6(0) 23.7±0.71 8.55±1.45 None T2DM 42.7±31.89(months) (0.88±0.05)×106 Elbow vein 33.2±2.82
Liu 2014 [19] WJ-MSCs 52.9± 10.5 22(7) 25.1 ± 2.4 8.20 ±1.69 7.53 ± 2.67 T2DM 8.7 ± 4.3(years) 1×106/kg Spleen artery 12
Kong 2014 [28] hUC -MSCs
Control
52.75± 12.69 8(3)
10(3)
25.94± 4.11
26.75± 4.32
7.30±1.49
None
9.17± 1.92
8.42±1.25
T2DM 6.87± 4.73(years)
11.4± 8.38 (years)
1.8×106/kg IV 6
Hu 2016 [29] WJ-MSCs
Control
52.43±4.88
53.21±8.22
31(14)
30(14)
26.74±5.41
27.03±6.68
7.67±1.23
7.54±1.31
8.24±1.55
7.91±1.44
T2DM 8.93±5.67(years)
8.3±6.07 (years)
1×106/kg IV 36
Jiang 2011 [30] PD-MSCs 66 10(3) None 9.8±2.2 None T2DM 3–20(years) 1.35 ×106/kg IV 3
  1. Abbreviations: BMI body mass index, HbA1c glycated hemoglobin, FBG fasting blood glucose, DM diabetes mellitus, T1DM type 1 diabetes, T2DM type 2 diabetes, SPD superior pancreaticoduodenal artery, hBM-MSCs human bone marrow mesenchymal stem cells, hUC-MSCs human umbilical cord mesenchymal stem cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells, AD-MSCs adipose mesenchymal stem cells, PD-MSCs placenta-derived mesenchymal stem cells